Showing results (161-170 of 177) with videos related to

Sort By:
Pageof 18
Journal of Clinical Medicine|May 14, 2025
Cardio-Oncology Challenges in Elderly PatientsEster Topa, Eliana De Rosa, Alessandra Cuomo, et al.
Frontiers in Immunology|March 12, 2026
Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?Linda Cerbone, Giandomenico Roviello, Fabio Calabrò, et al.
Current Oncology (Toronto, Ont.)|June 25, 2026
Real-World Analysis of Metastatic Renal Cell Carcinoma Patients Treated with Pembrolizumab Plus Axitinib: Evidence from the Campania Oncology NetworkMarilena Di Napoli, Elisabetta Coppola, Carmine D'Aniello, et al.
The Oncologist|December 2, 2025
Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort studyLorena Incorvaia, Mattia Puglisi, Marco Maruzzo, et al.
European Urology Open Science|November 24, 2025
Efficacy of Enfortumab Vedotin After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the ARON-2EV CohortOndrej Fiala, Francesco Grillone, Kazutoshi Fujita, et al.
Targeted Oncology|May 5, 2024
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)Ondřej Fiala, Sebastiano Buti, Aristotelis Bamias, et al.
European Journal of Cancer (Oxford, England : 1990)|April 26, 2023
Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma IntergroupMarco Rubatto, Paolo Fava, Ignazio Stanganelli, et al.
Minerva Urology and Nephrology|April 23, 2026
Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study)Marco Maruzzo, Alexandr Poprach, Sebastiano Buti, et al.
Molecular & Cellular Proteomics : MCP|May 9, 2015
Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast CancerChristian D Young, Lisa J Zimmerman, Daisuke Hoshino, et al.
European Urology Open Science|October 30, 2024
Prostate-specific Antigen at 3 Months as a Predictor of Radiologic Progression-free Survival in Metastatic Hormone-sensitive Prostate Cancer Treated with Apalutamide: Analysis of 633 Patients in a Real-world DatabaseMario Hassi Roman, Kinga Mate, Pedro De Pablos-Rodriguez, et al.
Pageof 18